Hong Kong, 30 March 2026 — Beijing Biostar Pharmaceuticals Co., Ltd. has received approval from the Listing Committee of The Stock Exchange of Hong Kong Limited (HKEX) for the conversion and full circulation listing of 147.87 million unlisted shares. The clearance, granted on 20 March 2026, will allow these shares—previously unlisted and representing 40.6 % of the company’s share capital—to commence trading as H-shares.

Prior to the transaction, Beijing Biostar’s share structure comprised 216.72 million H-shares (59.4 %) and 147.87 million unlisted shares (40.6 %), yielding a total of 364.59 million shares outstanding. Post-conversion, the total share count remains unchanged, but the company’s entire capital will be represented by H-shares, enhancing secondary-market liquidity and broadening investor access.

A total of 20 investors are involved in the conversion. The three largest participants—SDIC (Shanghai) Technology Transfer Venture Capital Fund, Baygen QT Inc., and Beijing Chongde Hongxin Venture Capital Center—will hold 8.10 %, 5.56 % and 4.26 % of the company’s enlarged H-share base, respectively. No individual shareholder will exceed a 10 % stake as a result of the conversion.

The company first disclosed the application on 6 February 2026 following receipt of a filing notice from the China Securities Regulatory Commission. With HKEX approval in place, completion of the conversion and listing is now subject to customary procedural steps.

Investors are advised to exercise caution when dealing in Beijing Biostar Pharmaceuticals’ shares.